Moreover, EPO treatment in hematologic patients improved the response to influenza vaccination63 and normalized the levels of impaired CD4+ and CD8+ T cell and CD4+CD25+ cell numbers in low risk myelodysplastic syndrome patients (MDS)64. This evidence concerns the gene EPO and myelodysplastic syndrome.